Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.67 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
| ▸ | HMGCR | P04035 | 2/20 | 0.56 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419163 | 1.00 | RXRA (0.67) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL27560748 | 0.95 | RXRA (0.62) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| Quinoline SCHEMBL28262813 | 0.91 | RXRA (0.58) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL18696397 | 0.88 | RXRA (0.65) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL1843198 | 0.88 | RXRA (0.75) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL1844436 | 0.88 | RXRA (0.75) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL29466456 | 0.88 | RXRA (0.75) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL8846271 | 0.87 | RXRA (0.64) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL28287583 | 0.87 | RXRA (0.64) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL526489 | 0.85 | RXRA (0.68) | RXRAPRKAA2NR1I2NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444500-A | Preparation method of pitavastatin calcium olefin epoxidation impurity | 南京长澳医药科技有限公司 | 2023-07-18 | — | — | CN | claimed |
| CN-109574999-B | Preparation method of pitavastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2022-03-08 | — | — | CN | claimed |
| CN-106279016-B | A kind of 2- cyclopropyl -4-(4- fluoro-phenyl) -3- quinoline aldehyde synthetic method | 黄河三角洲京博化工研究院有限公司 | 2019-01-08 | — | — | CN | claimed |
| EP-2788342-B1 | PROCESS FOR THE PREPARATION OF A STATIN PRECURSOR | DSM SINOCHEM PHARM NL BV (NL) | 2018-01-24 | — | — | EP | claimed |
| CN-103974946-B | The method for preparing statin precursor | 中化帝斯曼制药有限公司荷兰公司 | 2017-09-29 | — | — | CN | claimed |
| CN-106279016-A | A kind of synthetic method of 2 cyclopropyl 4 (4 fluorophenyl) 3 quinoline aldehydes | 黄河三角洲京博化工研究院有限公司 | 2017-01-04 | — | — | CN | claimed |
| EP-2665722-B1 | PROCESS FOR THE PREPARATION OF DIOL SULFONES | DSM SINOCHEM PHARM NL BV (NL) | 2016-08-17 | — | — | EP | claimed |
| US-9150562-B2 | Process for the preparation of diol sulfones | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2015-10-06 | — | — | US | claimed |
| EP-2665721-B1 | METHYLTETRAZOLE SULFIDES AND SULFONES | DSM SINOCHEM PHARM NL BV (NL) | 2015-07-08 | — | — | EP | claimed |
| CN-103145613-B | Method for synthesizing (E)-3-[2-cyclopropyl-4-(4-fluorophenyl) quinolinyl-2-propenal | YELLOW RIVER DELTA JINGBO RES INST CHEMICAL IND CO LTD | 2015-04-08 | — | — | CN | claimed |
| US-20040077866-A1 | Process for producing quinoline carboxyaldehyde derivative and intermediate thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-22 | — | — | US | claimed |
| EP-1391455-A1 | PROCESS FOR PREPARATION OF A QUINOLINECARBALDEHYDE | Daicel Chemical Industries, Ltd. (JP) | 2004-02-25 | — | — | EP | claimed |
| US-20040030139-A1 | Process for producing (3R,5S)-(E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin- 3-yl]-3, 5-dihydroxyhept-6-enic acid esters | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-02-12 | — | — | US | claimed |
| EP-1365029-A1 | PROCESS FOR PRODUCING (3R,5S)-(E)-7- 2-CYCLOPROPYL-4-(4-FLUOROPHENYL)-QUINOLIN-3-YL]-3,5-DIHYDROXYHEPT-6-ENIC ACID ESTERS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-11-26 | — | — | EP | claimed |
| EP-1361215-A1 | PROCESS FOR PRODUCING QUINOLINE CARBOXYALDEHYDE DERIVATIVE AND INTERMEDIATE THEREOF | Nissan Chemical Industries, Ltd. (JP) | 2003-11-12 | — | — | EP | claimed |
| US-6541636-B2 | Such as 3-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl) prop-2-enenitrile by reacting 2-cyclopropyl-4-(4-fluorophenyl) quinoline-3-carbaldehyde with acetonitrile in the presence of base, then dehydrating; enzyme inhibitors | UBE INDUSTRIES, LTD. (JP) | 2003-04-01 | — | — | US | claimed |
| US-20030013885-A1 | PROCESS FOR PREPARING QUINOLYLACRYLONITRILE AND INTERMEDIATES THEREFOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-16 | — | — | US | claimed |
| EP-1251123-A1 | PROCESS FOR PREPARING QUINOLYLACRYLONITRILE AND INTERMEDIATES THEREFOR | Ube Industries, Ltd. (JP) | 2002-10-23 | — | — | EP | claimed |
| US-6437135-B1 | OXIDIZING 2-CYCLOPROPYL-4-(4-FLUOROPHENYL)-3-HYDROXYMETHYLQUINOLINE WITH A HYPOHALOGENOUS ACID SALT AND A QUATERNARY AMMONIUM SALT TO PRODUCE 2-CYCLOPROPYL-4-(4-FLUOROPHENYL)-QUINOLINE-3-CARBALDEHYDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-20 | — | — | US | claimed |
| EP-1142876-A1 | PROCESS FOR PRODUCING QUINOLINECARBALDEHYDE | Nissan Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030139-A1 | Process for producing (3R,5S)-(E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin- 3-yl]-3, 5-dihydroxyhept-6-enic acid esters | DHCR7, DHPS, HPD | RXRA 1107/4885PRKAA2 856/4885NR1I2 1486/4885 |
| US-20040077866-A1 | Process for producing quinoline carboxyaldehyde derivative and intermediate thereof | CPNE4, CYP3A4, CYP4B1 | RXRA 4470/4885PRKAA2 2622/4885NR1I2 3259/4885 |
| US-20030013885-A1 | PROCESS FOR PREPARING QUINOLYLACRYLONITRILE AND INTERMEDIATES THEREFOR | WEE2, WEE1, CYP4F11 | RXRA 3421/4885PRKAA2 3505/4885NR1I2 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.